Kaiser Poll Show Support for Personal Imporatation

Kaiser Poll Show Support for Personal Imporatation

Tuesday, July 26, 2016

We Can’t Wait: Making the case for Personal importation of prescription medicines as the primary immediate health care tool to lower costs and provide benefits to the health and well-being of Americans

For more than a quarter-century, Americans have been victims of the predatory pricing practices of Pharma.

It is time for a change! American patients can’t wait any longer!  

There is an answer, a strategy that can provide the touchstone for a bi-partisan approach to comprehensive legislation to allow Americans the health benefits of access to vital maintenance medicines, access that could very well be a key to deterring the illness and physical deterioration that too often lead to more drastic devastating illness that will require specialty medicines.

That answer is personal importation of brand-name prescription medicines from licensed, registered Pharmacies in Tier One countries whose standards of safety and efficacy meet or exceed those of the U.S.

That is why AmericanRxBillofRights submitted its Articles defining the rights of Americans to enjoy the health and personal well-being benefits of access to personally imported medicines to Representatives, Senators and even the Platform Committees of the Republican and Democratic parties.

We did this because the challenge lies with our political leadership.  The Presidential candidates have offered their support of many of the provisions laid out in the AmericanRxBillofRights, so it is now the voters who must call out their Congressional candidates to demand answers about the harmful impacts of the predatory pricing practices of Pharma.

The first step is to define the results of the failure of Congress to act, and why we can’t wait any longer. Consider the results of Congress’ failure:
  • Result #1—A denial for millions of Americans to be able to exercise their right to the health benefit made possible from access to a regimen of vital life-line brand-name medicines, simply because they are unaffordable;
  • Result # 2—The ‘hoped-for’ answer to the scourge of unaffordable medicines—generic medicines—have seen price spikes that have made many of them equally unavailable to American patients;
  • Result # 3—Literally millions of Americans suffer from diseases—many of them life-threatening—raising the question of a possible link to the cause-effect impact of the denial of vital personally imported maintenance medicines that could have benefited patients and deterred the harmful effects of their disease;
  • Result # 4—Pharma raises prices on specialty medicines to thousands of dollars for treatments, even though many of the costly medicines are older, lower-cost medicines, and manufacturers are simply taking advantage of the illness of Americans;
  • Result # 5—Congress becomes indignant, holds hearings, witness testify, advocacy groups coalesce to ‘address’ price challenges, but…prices remain high, Congress continues with more hearings…and Americans continue to pay the highest prices in the world…WHY?;
  • Result #6--Because Pharma and its allies in the House of Representatives and the U.S. Senate who are the beneficiaries of Pharma’s extensive contributions have controlled the discussion on how to lower prescription and health care costs Pharma continues to rake in obscene profits, and American patients continue to be denied their medicines.
  • Here is a series of questions to ask the candidates in your Congressional districts and U.S. Senate races:
  • 1.     In light of the wide-spread bi-partisan support of personal importation for at least 16 years, sponsorship and support of legislation from the leadership of both political parties including the President, and the three major candidates of the Democratic and Republican Party this year, why has there been no adoption of personal importation;
  • 2.    If the answer is the ‘certification’ of the safety of the medicines by the Secretary of Health and Human Services, could you please provide the names and responsibilities of other Cabinet members who are legislatively made personally responsible for certifying the health impact of regulations, decisions, policies of their particular departments?
  • 3.    There are many groups that are being formed to ‘study’ the harmful impacts of recent price increases such as the spike in generic drug costs, and, of specialty medicines.  Unfortunately, the new groups being formed will require time—perhaps more than a year—to develop a consensus on the scope of the problems. Strategies to address the challenge of high prices will take even longer, ironically, since enactment of legislation to allow personal importation can offer immediate relief.
  • 4.    And, this leads to a final set of questions:
  • a.    If you are not a sponsor or co-sponsor of a bill to allow personal importation, why not?  If you are a supporter of personal importation, why do you believe your efforts have not gained traction?
  • b.    Does the problem lie within Congress itself?  For years, the Democrats controlled the House and Senate. Now, the Republicans have had control of the House and Senate for six years, and have failed to even bring the issue to a vote.  Does this indicate that politics take precedence over the health of your constituents?
  • c.     Irrespective of the cause, what is your strategy to advance the case for personal importation and lowering prescription drug costs?
  • d.    Are there stumbling blocks that public action by advocacy groups and the millions of Americans for whom personal importation is a vital lifeline, can help remove?
Relief will come only when the American voter finally speaks up and takes the initiative to clearly demand that Congress act.  Americans pay the highest costs for prescription medicines in the world.  We truly Can’t Wait anymore.  The cost in terms of illness, costs, and denial of the rights of Americans to have access to good health is too immense for further delays especially when it is within the ability of Congress to offer a solution.

No comments: